Hai Li
-
- Cancer Treatment and Pharmacology 3
- Cancer Cells and Metastasis 3
- Drug Transport and Resistance Mechanisms 2
- Chemokine receptors and signaling 2
- Pancreatic and Hepatic Oncology Research 2
- HER2/EGFR in Cancer Research 2
-
- Chemotherapy-induced cardiotoxicity and mitigation 2
-
- Immunotherapy and Immune Responses 2
- Co-authors
- Shikuo RongNils NickelKazuya MiyagawaLingli WangQuan ShangAshok K. BattaCaiyun G. LiGuorong Xu
- Partner nations
- ChinaUnited StatesItaly
In The Last Decade
Hai Li
19 papers receiving 353 citations
Peers
Comparison fields: 5 of 72
- Oncology 121
- Cancer Research 56
- Pulmonary and Respiratory Medicine 110
- Immunology and Allergy 15
- Cardiology and Cardiovascular Medicine 54
Countries citing papers authored by Hai Li
This map shows the geographic impact of Hai Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hai Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hai Li more than expected).
Fields of papers citing papers by Hai Li
This network shows the impact of papers produced by Hai Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hai Li. The network helps show where Hai Li may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hai Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 3 | |
| 2 | 2024 | 3 | |
| 3 | 2024 | 1 | |
| 4 | 2022 | 1 | |
| 5 | 2022 | 1 | |
| 6 | 2022 | 4 | |
| 7 | 2020 | 8 | |
| 8 | 2020 | 36 | |
| 9 | 2020 | 2 | |
| 10 | Correlation of HER2 codon 655 polymorphism with cardiotoxicity risk in Chinese HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab adjuvant chemotherapy. | 2020 | 8 |
| 11 | 2018 | 17 | |
| 12 | 2018 | 18 | |
| 13 | 2017 | 25 | |
| 14 | 2015 | 102 | |
| 15 | 2015 | 50 | |
| 16 | 2015 | 20 | |
| 17 | 2012 | 4 | |
| 18 | [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients]. | 2006 | 2 |
| 19 | 2004 | 51 |
About Hai Li
Hai Li is a scholar working on Oncology, Radiological and Ultrasound Technology and Cell Biology, having authored 19 papers that have together received 356 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (3 papers), Cancer Cells and Metastasis (3 papers), Drug Transport and Resistance Mechanisms (2 papers), Chemokine receptors and signaling (2 papers), Pancreatic and Hepatic Oncology Research (2 papers), Immunotherapy and Immune Responses (2 papers), HER2/EGFR in Cancer Research (2 papers) and Chemotherapy-induced cardiotoxicity and mitigation (2 papers). The work is most often cited by research in Oncology (121 citations), Cancer Research (56 citations) and Pulmonary and Respiratory Medicine (110 citations). Hai Li has collaborated with scholars based in China, United States and Italy. Frequent co-authors include Shikuo Rong, Nils Nickel, Kazuya Miyagawa, Lingli Wang, Quan Shang, Ashok K. Batta, Caiyun G. Li, Guorong Xu, Aiqin Cao and Jaya Bollineni. Their work appears in journals such as Scientific Reports, Molecular Carcinogenesis, Cancer Biomarkers, Functional & Integrative Genomics and International Journal of Biological Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.